Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Score 3
2022 pubmed 5 citations

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children.

Metbulut. Azize Pınar AP; Adıgüzel. Keziban Toksoy KT; İslamoğlu. Candan C; Boyraz. Mehmet M; Mısırlıoğlu. Emine Dibek ED

Key Findings

  • Overall hypersensitivity reactions were very rare (0.69%) among 1,010 pediatric patients
  • No cases of anaphylaxis were observed with triptorelin or leuprolide
  • Mild adverse events included sterile abscesses, hand tremor, vomiting, urticarial rash, and musculoskeletal stiffness

Practical Outcomes

  • Triptorelin can be used for puberty control with confidence that severe allergic reactions are exceedingly unlikely. Users should still watch for minor skin or muscle symptoms and report them, but routine pre‑emptive allergy testing isn’t needed for most people.

Summary

In a study of 1,010 kids with early puberty who got the hormone drug triptorelin (or leuprolide), only seven had mild side effects (about 0.7%). None had life‑threatening allergic reactions. The mild issues were things like tiny skin abscesses, hand tremors, a rash, vomiting, or muscle stiffness, and they resolved without serious problems.

Abstract

Gonadotropin releasing hormone analogues (GnRHa) are commonly used to treat central precocious puberty (CPP). Generally, they are well-tolerated; however adverse reactions have been reported. Local adverse events occur in 10-15% of the patients who were treated with GnRHa. Anaphylactoid reactions with GnRHa are very rarely seen. The aim of this study is to report our clinical experience with hypersensitivity reactions seen in pediatric patients receiving leuprolide acetate (LA) and triptorelin acetate (TA) in CPP at the single pediatric tertiary medical center and to evaluate the incidence rate of hypersensitivity reactions. This retrospective study included children with CPP who were treated with GnRHa (LA and TA) at our hospital between January 2013 and December 2020. We analyzed clinical characteristics of patients who experienced adverse reactions and analyzed the incidence rate. Seven side effects (adverse reactions) (0.69%) were observed among total of 1010 CPP patients who were treated with TA and LA. Sterile abscesses were observed in 3 patients (0.29%). None of the patients had an anaphylaxis. Tremors of both hands, a vomiting episode, an urticarial rash, and musculoskeletal stiffness were observed in one patient each. In our study, mild reactions were seen in 7 patients. GnRHa can be safely used and well-tolerated medications; but exceedingly rare, severe reactions can be developed.

Study Information

Provider

pubmed

Year

2022

Date

2022-02-17T00:00:00.000Z

DOI

10.4103/ijem.ijem_333_21

Citations

5

References

29